![Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab]()
Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumabGualberto, A; Hixon, M L; Karp, D D; Li, D; Green, S; Dolled-Filhart, M; Paz-Ares, L G; Novello, S; Blakely, J; Langer, C J; Pollak, M N · British Journal of Cancer · 2012